Arrowhead Pharmaceuticals, Inc. (ARWR) financial statements (2020 and earlier)

Company profile

Business Address 225 SOUTH LAKE AVENUE
PASADENA, CA 91101
State of Incorp. DE
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments50225977668599154
Cash and cash equivalents46122230258581133
Short-term investments41374641 1822
Receivables11000  
Prepaid expense3311131
Other current assets2311410
Total current assets:508265796891103155
Noncurrent Assets
Operating lease, right-of-use asset10 
Property, plant and equipment262314161554
Long-term investments and receivables2644    23
Long-term investments2644    23
Intangible assets, net (including goodwill)1717192022251
Intangible assets, net (excluding goodwill)1717192022251
Other noncurrent assets00000  
Other undisclosed noncurrent assets     00
Total noncurrent assets:80853336382928
TOTAL ASSETS:588350112104128132183
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1919121221147
Accounts payable128341253
Accrued liabilities4755551
Employee-related liabilities3543443
Deferred revenue5478
Debt0 00000
Deferred rent credit 00
Derivative instruments and hedges, liabilities   1214
Deferred revenue and credits6300
Other liabilities0000000
Other undisclosed current liabilities  0    
Total current liabilities:74971219261612
Noncurrent Liabilities
Long-term debt and lease obligation14 22311
Long-term debt, excluding current maturities  223  
Capital lease obligations   11
Operating lease, liability14 
Liabilities, other than long-term debt 922500
Deferred revenue and credits25  
Deferred revenue 5
Deferred rent credit 42
Other liabilities  00000
Other undisclosed noncurrent liabilities     64
Total noncurrent liabilities:14944875
Total liabilities:881061623332317
Stockholders' equity
Stockholders' equity attributable to parent500245968196110167
Preferred stock    000
Common stock0000000
Additional paid in capital922664583514494427391
Accumulated other comprehensive income (loss)(0)(0)(0)00(0) 
Accumulated deficit(422)(419)(487)(433)(398)(317)(225)
Stockholders' equity attributable to noncontrolling interest(1)(1)(1)(1)(1)(1)(1)
Total stockholders' equity:500244958195110166
TOTAL LIABILITIES AND EQUITY:588350112104128132183

Income statement (P&L) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
Gross profit:1641691631000
Operating expenses(118)(108)(72)(68)(82)(96)(53)
Operating income (loss):4561(56)(37)(82)(96)(53)
Nonoperating income (expense)871304(5)
Investment income, nonoperating(1)(1)   (1) 
Other nonoperating income  01000
Interest and debt expense      (0)
Income (loss) from continuing operations before equity method investments, income taxes:5368(54)(34)(82)(92)(59)
Loss from equity method investments      (0)
Other undisclosed income from continuing operations before income taxes      0
Income (loss) from continuing operations before income taxes:5368(54)(34)(82)(92)(59)
Income tax expense (0)(0)(0)(0)(0)(0)
Other undisclosed loss from continuing operations(0)      
Net income (loss):5368(54)(34)(82)(92)(59)
Net income attributable to noncontrolling interest      0
Net income (loss) available to common stockholders, diluted:5368(54)(34)(82)(92)(59)

Comprehensive Income ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
9/30/2014
Net income (loss):5368(54)(34)(82)(92)(59)
Comprehensive income (loss):5368(54)(34)(82)(92)(59)
Comprehensive income, net of tax, attributable to noncontrolling interest      0
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)(0)00(0) 
Comprehensive income (loss), net of tax, attributable to parent:5368(55)(34)(82)(92)(59)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: